The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
434
The objective of this study is to investigate if 8 weeks of treatment with flexible doses of bifeprunox (20 to 40 mg/day) is superior to treatment with placebo in depressed outpatients with bipolar disorder.
Using the change from baseline to endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS), total score as the primary efficacy endpoint
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Beverly Hills, California, United States
Unnamed facility
National City, California, United States
Unnamed facility
Stanford, California, United States
Unnamed facility
Farmington Hills, Connecticut, United States
Unnamed facility
Bradenton, Florida, United States
Unnamed facility
Jacksonville, Florida, United States
Unnamed facility
Orlando, Florida, United States
Unnamed facility
West Palm Beach, Florida, United States
Unnamed facility
Smyrna, Georgia, United States
...and 30 more locations